Acknowledgments
The authors thank Andrea Panzeri and Gabriella Baldi (ASST Fatebenefratelli-Sacco) for performing some of the laboratory measurements.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Clinical and Laboratory Standards Institute (CLSI). Evaluation of detection capability for clinical laboratory measurement procedures, approved guideline – 2nd ed. CLSI document EP17-A2, 2012. https://clsi.org/standards/products/method-evaluation/documents/ep17/. Accessed: 20 June 2019.Search in Google Scholar
2. Paffenholz P, Grein K, Heidegger I, Nestler T, Grabbert M, Salem J, et al. Predictors of thrombosis in testicular cancer during platinum-based chemotherapy. World J Urol 2019;37:1907–16.10.1007/s00345-018-2598-7Search in Google Scholar PubMed
3. Lempiäinen A, Hotakainen K, Blomqvist C, Alfthan H, Stenman UH. Increased human chorionic gonadotropin due to hypogonadism after treatment of a testicular seminoma. Clin Chem 2007;53:1560–1.10.1373/clinchem.2007.088518Search in Google Scholar PubMed
4. Ferraro S, Panteghini M. A step forward in identifying the right human chorionic gonadotropin assay for testicular cancer. Clin Chem Lab Med 2020;58:357–60.10.1515/cclm-2019-0319Search in Google Scholar PubMed
5. Ferraro S, Trevisiol C, Gion M, Panteghini M. Human chorionic gonadotropin assays for testicular tumors: closing the gap between clinical and laboratory practice. Clin Chem 2018;64:270–8.10.1373/clinchem.2017.275263Search in Google Scholar PubMed
6. Korhonen J, Alfthan H, Ylostalo P, Ylöstalo P, Veldhuis J, Stenman UH. Disappearance of human chorionic gonadotropin and its alpha- and beta-subunits after term pregnancy. Clin Chem 1997;43:2155–63.10.1093/clinchem/43.11.2155Search in Google Scholar
7. Fabre E, Jira H, Izard V, Ferlicot S, Hammoudi Y, Theodore C, et al. “Burned-out” primary testicular cancer. BJU Int 2004;94:74–8.10.1111/j.1464-410X.2004.04904.xSearch in Google Scholar PubMed
8. Balalaa N, Selman M, Hassen W. Burned-out testicular tumor: a case report. Case Rep Oncol 2011;4:12–5.10.1159/000324041Search in Google Scholar PubMed PubMed Central
9. Mosillo C, Scagnoli S, Pomati G, Caponnetto S, Mancini ML, Bezzi M, et al. Burned-out testicular cancer: really a different history? Case Rep Oncol 2017;10:846–50.10.1159/000480493Search in Google Scholar PubMed PubMed Central
10. Lempiäinen A, Sankila A, Hotakainen K, Haglund C, Blomqvist C, Stenman UH. Expression of human chorionic gonadotropin in testicular germ cell tumors. Urol Oncol 2014;32:727–34.10.1016/j.urolonc.2013.11.007Search in Google Scholar PubMed
11. Handwerger S, Wilson SP, Tyrey L, Conn PM. Biochemical evidence that human placental lactogen and human chorionic gonadotropin are not stored in cytoplasmic secretion granules. Biol Reprod 1987;37:28–32.10.1095/biolreprod37.1.28Search in Google Scholar PubMed
12. Cathomas R, Klingbiel D, Bernard BD, Lorch A, del Muro XG, Morelli F, et al. FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: results of an International Global Germ Cell Cancer Group (G3) registry. J Clin Oncol 2017;35(Suppl):4521.10.1200/JCO.2017.35.15_suppl.4521Search in Google Scholar
©2020 Walter de Gruyter GmbH, Berlin/Boston
